Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company UpdateGlobeNewsWire • 08/12/24
Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of DirectorsNewsfile Corp • 07/01/24
Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company UpdateGlobeNewsWire • 05/14/24
Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke NetworkGlobeNewsWire • 05/02/24
Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key CatalystsGlobeNewsWire • 04/30/24
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1GlobeNewsWire • 04/23/24
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal ContraceptiveGlobeNewsWire • 04/11/24
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company UpdateGlobeNewsWire • 03/28/24
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024GlobeNewsWire • 03/21/24
Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024GlobeNewsWire • 01/31/24
Daré Bioscience Announces Grant to Support Biotherapeutic Product DevelopmentGlobeNewsWire • 01/17/24
Daré Bioscience's DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women's Health as well as in Treating a Broad Range of DiseasesGlobeNewsWire • 01/04/24
Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical StudyGlobeNewsWire • 12/20/23
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical StudyGlobeNewsWire • 12/13/23
Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company UpdateGlobeNewsWire • 11/09/23